Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Urolithin A is a naturally occurring small molecule metabolite produced by the transformation of ellagitannins (found in foods like pomegranates and walnuts) by gut microbiota[6][5]. It is not present in food directly but results from microbial metabolism. Urolithin A has demonstrated antioxidant and anti-inflammatory properties and acts as an activator of mitophagy—the selective degradation of mitochondria via autophagy—thereby improving mitochondrial function and cellular health[1][2][4]. Mechanistically, it activates pathways such as PINK1/Parkin-mediated mitophagy and modulates signaling through Nrf2 and AMPK/PPARγ[2]. Preclinical studies suggest benefits for muscle health (promoting muscle protein synthesis), neuroprotection (potentially relevant to Alzheimer’s disease), metabolic diseases (type 2 diabetes mellitus), cardiovascular health, anti-aging effects, and cancer prevention[2][5][7]. Urolithin A is being developed primarily as a dietary supplement for healthy aging; clinical development status includes early-phase human trials with no major safety concerns reported over short durations[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Urolithin A.